We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Chemical Profiles for Infectious Diarrhea Diagnose Diseases

By HospiMedica staff writers
Posted on 12 Mar 2007
Smells from healthy feces and people with infectious diarrhea differ significantly in their chemical composition and could be used to diagnose quickly diseases such as Clostridium difficile. More...


A study, published online in the February 2007 edition of the online journal FASEB, is the result of a joint collaboration between Dr. Chris Probert, Consultant and Reader in gastroenterology at Bristol University (Bristol, UK) and Professor Norman Ratcliffe at the University of the West of England (Bristol, UK). The study will appear in the June 2007 issue of the printed journal.

For a long time it has been known that stools have distinctive and different odors if there is an infection. What the scientists have done is to take this 'knowledge' a step further by analyzing the odor of healthy donors and patients with gastrointestinal disease to see if precise chemical profiles can be established. The scientists compared feces of healthy donors together with patients with ulcerative colitis, C jejuni, and C difficile and found that the chemical composition of each was significantly different.

Dr Chris Probert said, The discovery of chemical profiles is a major step forward in the diagnosis and treatment of people with gastrointestinal disease. Early treatment of C difficile means patients have a much better chance of survival and fewer complications. However, at present the average length of time taken to diagnose the condition is eight days.

Two of the most common types of infectious diarrhoea are Campylobacter jejuni and C difficile. Although less well known than the methicillin-resistant Staphylococcus aureus (MRSA), C difficile is just as serious, and affects more than 50,000 people each year in England and Wales at a cost to the National Health Service (NHS) of around UK£60 million.

Dr Chris Probert added, There is a huge potential for a rapid diagnosis device in the UK, 30,000 samples are tested in Bristol alone each year. However, the device could be adapted for use in developing countries where 7,000 children die as a result of diarrhea every day. Our next aim is to produce a prototype device capable of diagnosing at any healthcare setting.

Professor Norman Ratcliffe, from the University of the West of England, added, There are numerous different kinds of infection that cause diarrhoea and a speedy diagnosis would lead to more appropriate use of antibiotics. A rapid diagnosis device has the potential to save lives and reduce the cost burden to the National Health Service [NHS; UK]. Early isolation of infectious patients would reduce hospital outbreaks leading to fewer ward/hospital closures.


Related Links:
Bristol University
University of the West of England

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Syringe Pump
SP50 Series
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.